INTI Inhibitor Therapeutics Inc.

Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. It focuses on SUBA-Itraconazole, a patented, oral formulation of Itraconazole, for treatment of prostate and lung cancers. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.13    OTCQB
As of 01/27/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  10/30/1997
Outstanding shares:  376,858,323
Average volume:  1,938
Market cap:   $49,217,697
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -384.96
PB ratio:   -9.32
PS ratio:   0.00
Return on equity:   9.07%
Net income %:   -771.45%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy